May 4th 1st quarter earnings report. Beginning of the end.

Discussion in 'Esperion' started by anonymous, May 4, 2021 at 10:08 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    It just wasn't meant to be. The sales weren't there at the beginning of the launch. We sputtered through 2021 with 700k first quarter, 3.2 mill 2nd quarter, 5 mill 3rd and 8 mill 4th. This is in the lipid market and the penetration into the market just hasn't happened . The sales results for the 1st quarter was well below expectations. Some posts about 20 million had been thrown around but Esperion ended up doing 6.4 million. This isn't even paying for about a region. Not sure where we go from here. This was very bad folks and I can only imagine the pressure that's coming.
     

  2. anonymous

    anonymous Guest

    This was a bust. Esperion can't even run a call without numerous technical difficulties. All done on purpose to hide the double talk and massaging of numbers. Big talk about how rebates and copay cards effected total revenue. Even with the pre-planted question saying it really was 11 million in revenue is more double talk. Rebates and co-pay cards are the cornerstones of prescription medicines. Stop using this as another excuse along with covid. Also stop dancing around flat script growth. Outside of a few weeks early in the quarter when patients renew their scripts at the beginning of Jan that was the only growth and it was small. Tim and his band of misfits are experts at deflection and double talk. In no way was this a positive call. The 3rd party partnerships are nothing but a money train that is used as an ATM machine for Esperion. No talk about layoffs and realigning territories and still no growth. 6.4 million in revenue and 90 million dollar loss. Covid Covid Covid. Plenty of companies are getting it done but not Esperion even talking about spikes in January. When haven't we had spikes. This was very bad and we shall see what the stock market says today in response to this bad quarterly report.
     
  3. anonymous

    anonymous Guest

    Stock down pre hours over $7 a job well done for the entire Esperion Team
    Stock options are worthless, more layoffs, cut in spending will be the next steps.

    Sheldon working his magic , similar to his Sanofi days
    Those Kos hires really are performing at a high level.
     
  4. anonymous

    anonymous Guest

    Sheldon was a Sanofi hack and the Kos crowd were all failures. How do these clowns on the board keep their jobs. Look at performance since launch. Completely botched the initial hiring process , sputtered out of the gate with the launch and poor sales results ever since.
     
  5. anonymous

    anonymous Guest

    Stock down 20%. A total bloodbath. People who got screwed over in interview process are dancing in the streets today!! What goes around comes around!! Payback !!! So glad to be on the outside looking in with a true legitimate biological company. Bon Voyage Esperion!!!
     
  6. anonymous

    anonymous Guest

    I've got to be honest, I heard good things about Sheldon was expecting good things. Instead, he came in and let the same spineless upper sales management continue their knee-jerk, reactionary bloodletting. Fix the problem, not the symptoms.
     
  7. anonymous

    anonymous Guest

    And do we really think were going to get preferred status on more plans in 2021. My office had PA's. There willing to do for PCSK9's as they offer such huge reductions but doctors in my territory don't classify BA in Repatha category.
     
  8. anonymous

    anonymous Guest

    Anyone who believes that coverage is coming is buying swampland. How can they keep this Ponzi scheme going?
     
  9. anonymous

    anonymous Guest

    I see there are some Repatha rep job openings at Amgen, I'm posting! Repatha took in 286 million 1q and that is a "small" product for them. I'd feel safer selling cardio for a company that took in 6 billion 1q. I do have a call setup with an Amgen friend to talk around having Esperion on my resume, will report back.

    Good luck to all.
     
  10. anonymous

    anonymous Guest

    Good company. Amgen can be tough to work for but money is good and more lateral moves for you. They spend more on electricity in a quarter than Amgen does in total business in a quarter. As long as you've selling in lipid space and have relationships that will be a plus. If anyone is still thinking there's a future at Esperion needs to listen to earnings call again and look what financial sector is saying about Esperions future.
     
  11. anonymous

    anonymous Guest

    I'm pretty confident they're going to keep the reps that are performing. My fat, oblivious manager is pretty confident in that. And once the ink dries on the Medicare contracts, we're golden. In three years, this stock will be solid.
     
  12. anonymous

    anonymous Guest

    Asshole has come out from under his rock. Like there going to keep these Scientifically Hired when the company is sold off to some 3rd world generic company. The only thing golden with this stock will be the same color your toilet paper is after some serious wipes. I take it you were oblivious on May 4th. Great hire.
     
  13. anonymous

    anonymous Guest

    Matthew in Clevelland...time for you to chase your Unlcle Jeff Vengley to a new position at another company....
     
  14. anonymous

    anonymous Guest

    These two are examples of The Peter Principle. Two of the biggest loads on two feet. With the exception of Tim ,Rick, Sheldon.
     
  15. anonymous

    anonymous Guest


    Watch out for the no compete clause . I think you signed when you got hired w Espr. Don’t know if they’d do anything tho.
     
  16. anonymous

    anonymous Guest

    Good to see a strong close to the week with the stock up over a buck today. Clearly the selling was over done; our future remain solid based upon the science that we have in the lipid space. I’m excited to see what the rest of this year brings, as the growth continues. Major tech companies often stumble on their way to greatness, and this is no exception. My doctors are starting to get more serious about aggressive lipid management as the market place opens up once again, our increased access will do nothing but drive further success. We are on the cusp of greatness.
     
  17. anonymous

    anonymous Guest

    The only thing you or Esperion are on the cusp of his hanging on for dear life on the toilet seat. Wow! Esperion closed at 22.00. Huge rally. Remember it bottom out at 17 after that wonderful encouraging 1st quarter report came out when it basically said Esperion shit the bed. 6.4 million in sales . Projection was 22million. Sounds like a miserable failure. Nobody cares about Esperion. Doctors are impressed since day 1. Just the usual dribble out of Ann Arbor on the previous post. It's against the law to use the word greatness in any context with Esperion. This week was an embarrassment. You should be ashamed at the sales results. You should be ashamed of the reps and all the dipshits you hired a year ago. GREAT JOB ESPERION.
     
  18. anonymous

    anonymous Guest

    The noncompete agreement is a joke !

    Do not let it inhibit you from moving on. Don't you have a Family ?

    Companies doing this are pathetic . While they can fire for no reason !!!!
     
  19. anonymous

    anonymous Guest

    Most states are Right to Work States and these noncompetes cannot be enforced.
    Plus, who will be left there to enforce it?
     
  20. anonymous

    anonymous Guest

    Again i will ask. Compete with what? That non-compete we signed was just a trick it intimidation. This was something Tim cooked up to inflate his ego. Remember how many pages that was? Like were dealing with uranium or something. Esperion doesn't have the financial resources to go after you and this would never stand up in court. Plus I know tons of my friends who left and are we working in cardiology. Some even in lipid space.